Eli Lil­ly’s ul­cer­a­tive col­i­tis drug ap­proved by FDA in crowd­ed mar­ket

Six months af­ter re­ject­ing Eli Lil­ly’s ul­cer­a­tive col­i­tis drug over man­u­fac­tur­ing is­sues, the FDA has now ap­proved the phar­ma gi­ant’s treat­ment, open­ing the doors to com­pe­ti­tion in a boom­ing mar­ket for in­flam­ma­to­ry bow­el dis­ease med­i­cines.

Lil­ly will start sell­ing the IV-in­fused mirik­izum­ab as Omvoh “in the com­ing weeks,” the In­di­anapo­lis-based phar­ma com­pa­ny said Thurs­day night. It marks the first of three high­ly-an­tic­i­pat­ed FDA de­ci­sions for Lil­ly this quar­ter, the oth­er two be­ing a chron­ic weight man­age­ment in­di­ca­tion for its di­a­betes drug Moun­jaro and a nod in Alzheimer’s for its po­ten­tial Leqem­bi com­peti­tor do­nanemab.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER